Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Inmunotek S.L. clinical trials
The registry lists 24 studies whose lead sponsor is Inmunotek S.L.. 11 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 23, 2026.
Keep track of what changes. Save the Inmunotek S.L. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Inmunotek S.L..
- Inmunotek S.L.24 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 24 of 24.
- Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or DfRecruitingNCT07348302Phase 3
- Determination of Blomia Tropicalis Allergen Extract in Prick Test UnitsNot yet recruitingNCT07195929Not applicable
- Efficacy and Safety Evaluation for the Treatment of Allergy Against MitesRecruitingNCT04435990Phase 3
- Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.RecruitingNCT04898283Phase 3
- Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive PollenRecruitingNCT04891237Phase 3
- Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom AllergyRecruitingNCT06782217
- Quercus Ilex and Quercus Robur Allergen Extracts StandardisationRecruitingNCT05532566Not applicable
- Immunotherapy for the Treatment of Hymenoptera Venom Allergy in Real-life Conditions.RecruitingNCT06790368
- Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood CellsRecruitingNCT05208060Phase 1/2
- Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen ExtractNot yet recruitingNCT05641272Phase 2/3
- Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/RhinoconjunctivitisNot yet recruitingNCT05400811Phase 3
- Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max ForteCompletedNCT07427576
- Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01842360Phase 2/3
- Phleum Pratense and Dactylis Glomerata Allergen Extracts StandardizationCompletedNCT06957496Not applicable
- Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.CompletedNCT05533385Not applicable
- Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/RhinoconjunctivitisTerminatedNCT04874714Phase 3
- Determination of the Sensitivity and Specificity of Prick Test Betula VerrucosaCompletedNCT02527187Phase 2
- Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen AllergyCompletedNCT02654223Phase 2
- Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 InfectionStatus unknownNCT04363814Phase 3
- Efficacy and Safety Evaluation in Recurrent Wheezing AttacksCompletedNCT01734811Phase 3
- Evaluation of the Efficacy and Safety of MV140CompletedNCT02543827Phase 3
- Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare PersonnelWithdrawnNCT04452643Phase 3
- Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite AllergyStatus unknownNCT02661854Phase 2
- Biological Stardadization of D. Pteronyssinus and D. Farinae Allergen ExtractsCompletedNCT02527122Not applicable